HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Massimo Cugno Selected Research

Lichenoid Eruptions

11/2015Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients With Inflammatory Bowel Diseases.
5/2014Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
1/2014Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Massimo Cugno Research Topics

Disease

16Inflammation (Inflammations)
12/2020 - 12/2002
14Chronic Urticaria
01/2022 - 05/2006
13Angioedema
09/2021 - 08/2002
8Necrosis
01/2019 - 07/2004
7Atypical Hemolytic Uremic Syndrome
01/2022 - 08/2013
6Urticaria (Hives)
09/2021 - 05/2006
6Rheumatoid Arthritis
12/2019 - 09/2008
5COVID-19
06/2022 - 01/2021
5Thrombotic Microangiopathies
01/2022 - 08/2013
5Skin Diseases (Skin Disease)
01/2019 - 09/2012
5Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/2015 - 11/2007
4Bullous Pemphigoid (Pemphigoid)
01/2022 - 09/2012
4Hypersensitivity (Allergy)
12/2021 - 09/2012
4Thrombosis (Thrombus)
11/2021 - 03/2004
4Blister (Bulla)
01/2019 - 09/2009
3Infections
03/2020 - 05/2014
3Edema (Dropsy)
01/2019 - 12/2002
3Lichenoid Eruptions
11/2015 - 01/2014
3Acquired angioedema
09/2013 - 12/2008
3Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2013 - 12/2008
3Hereditary Angioedemas
02/2013 - 02/2009
3Heart Failure
07/2005 - 12/2002
2HELLP Syndrome
12/2020 - 11/2012
2Autoimmune Diseases (Autoimmune Disease)
01/2019 - 04/2010
2Pyoderma Gangrenosum
04/2018 - 12/2014
2Hidradenitis Suppurativa
04/2018 - 12/2014
2Eczema
11/2015 - 01/2014
2Psoriasis (Pustulosis Palmaris et Plantaris)
11/2015 - 01/2014
2Neoplasms (Cancer)
04/2015 - 05/2014
2Skin Neoplasms (Skin Cancer)
05/2014 - 01/2014
2Cutaneous Lupus Erythematosus
05/2014 - 01/2014
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2014 - 01/2014
2Hemorrhage
01/2014 - 01/2014
2Paraproteinemias (Monoclonal Gammopathy)
09/2013 - 12/2008
2Sepsis (Septicemia)
04/2010 - 02/2009
2Myocardial Infarction
02/2010 - 04/2004
1Severe Acute Respiratory Syndrome
06/2022
1Wells syndrome
01/2022
1Cutaneous Mastocytosis
01/2022
1Erythema Multiforme
01/2022
1Purpura
01/2022
1Vasculitis (Vasculitides)
01/2022
1Cryopyrin-Associated Periodic Syndromes
01/2022

Drug/Important Bio-Agent (IBA)

17Complement System Proteins (Complement)IBA
01/2022 - 12/2008
11ThrombinFDA Link
12/2019 - 07/2004
11CytokinesIBA
01/2019 - 12/2002
10AutoantibodiesIBA
01/2021 - 12/2008
9BradykininIBA
09/2021 - 08/2002
8AntibodiesIBA
06/2022 - 03/2004
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2018 - 12/2002
7Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
09/2021 - 10/2002
7fibrin fragment D (D-dimer)IBA
12/2019 - 07/2004
6Biomarkers (Surrogate Marker)IBA
06/2022 - 07/2004
6Pharmaceutical PreparationsIBA
01/2022 - 01/2014
6Omalizumab (Xolair)FDA Link
12/2019 - 02/2014
6Thromboplastin (Tissue Factor)IBA
12/2018 - 03/2007
6C-Reactive ProteinIBA
01/2017 - 04/2004
5eculizumabFDA Link
01/2022 - 08/2013
5Peptides (Polypeptides)IBA
09/2021 - 07/2005
5Biological ProductsIBA
01/2019 - 09/2012
5Histamine Antagonists (Antihistamines)IBA
01/2019 - 03/2003
5Prothrombin (Factor II)IBA
05/2016 - 05/2006
5Interleukin-6 (Interleukin 6)IBA
05/2016 - 04/2004
4Immunoglobulin G (IgG)IBA
06/2022 - 03/2020
4Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
01/2021 - 10/2002
4Histamine (Histamine Dihydrochloride)FDA Link
01/2019 - 01/2009
4InterleukinsIBA
02/2018 - 09/2008
4Tissue Plasminogen Activator (Alteplase)FDA Link
01/2016 - 03/2004
4von Willebrand FactorIBA
01/2014 - 07/2004
3Immunoglobulin M (IgM)IBA
01/2022 - 03/2020
3Immunoglobulin A (IgA)IBA
01/2022 - 03/2020
3Immunoglobulin E (IgE)IBA
01/2019 - 04/2010
3AnticoagulantsIBA
01/2019 - 07/2004
3Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA
01/2013 - 02/2009
3Fibrinogen (Factor I)FDA Link
06/2012 - 07/2004
3Plasminogen Activators (Plasminogen Activator)IBA
06/2012 - 07/2004
2Complement Factor H (Factor H)IBA
01/2021 - 11/2012
2EnzymesIBA
12/2020 - 10/2011
2Peptide Hydrolases (Proteases)FDA Link
01/2019 - 03/2010
2Proteinase-Activated ReceptorsIBA
01/2019 - 03/2010
2Proteins (Proteins, Gene)FDA Link
01/2019 - 10/2014
2Antirheumatic Agents (DMARD)IBA
12/2018 - 04/2018
2Interleukin-17 (Interleukin 17)IBA
02/2018 - 08/2017
2Interleukin-1 (Interleukin 1)IBA
08/2017 - 12/2002
2Anti-Bacterial Agents (Antibiotics)IBA
03/2016 - 10/2013
2Adrenal Cortex Hormones (Corticosteroids)IBA
03/2016 - 01/2015
2Intravenous Immunoglobulins (IVIG)FDA Link
03/2016 - 01/2014
2Infliximab (Remicade)FDA Link
11/2015 - 09/2008
2AntigensIBA
01/2014 - 08/2002
2Factor VII (Proconvertin)IBA
06/2012 - 07/2004
2Heparin (Liquaemin)FDA LinkGeneric
01/2010 - 04/2004
2Factor XIIa (Coagulation Factor XIIa)IBA
07/2005 - 04/2004
2prothrombin fragment 1IBA
07/2004 - 04/2004
1Antigen-Antibody Complex (Immune Complex)IBA
01/2022
1DNA (Deoxyribonucleic Acid)IBA
01/2022
1Antihypertensive Agents (Antihypertensives)IBA
12/2021
1ChAdOx1 nCoV-19IBA
11/2021

Therapy/Procedure

12Therapeutics
12/2021 - 10/2002
2Glycemic Control
04/2010 - 02/2009
1Kidney Transplantation
12/2021